Overview

Hypha Labs, Inc. was a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets. The company provided pharmaceutical-grade analysis and testing to the cannabis industry to ensure product quality and reliability. In February 2024, Hypha Labs sold the assets of its wholly owned subsidiary Digipath Labs, Inc. and shifted its focus to the research, development and commercialization of a new bioreactor product called the Hypha Micropearl.

The Hypha Micropearl bioreactor is a home appliance designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The device, along with replaceable cartridges filled with nutrient formulations, allows users to grow high-quality mushroom mycelium called Micropearls in just 8 days. These Micropearls can then be incorporated into various foods and beverages. Hypha Labs believes this innovative bioreactor technology will disrupt traditional mushroom production methods and bring lab-quality nutrients into the home.

Over the next 9 months, Hypha Labs plans to continue the design, development and testing of the Hypha Micropearl bioreactor, with the goal of being able to market the product by the latter part of 2026. The company will initially produce a limited number of bioreactors at its headquarters for testing purposes before seeking a manufacturing arrangement outside the U.S. for commercial production.

Financial Performance

The following tables summarize Hypha Labs’ financial results for the three and nine months ended June 30, 2026 and 2025:

Three Months Ended June 30	2026	2025	Increase / (Decrease)

Operating Expenses: General and Administrative | $66,419 | $81,683 | $(15,264) Professional Fees | $29,534 | $454,344 | $(424,810) Total Operating Expenses | $95,953 | $536,027 | $(440,074) Operating Loss | $(95,953) | $(536,027) | $440,074 Total Other Income (Expense) - Net | $(208,804) | $(25,996) | $(182,808) Net Loss | $(304,757) | $(562,023) | $257,266

Nine Months Ended June 30	2026	2025	Increase / (Decrease)

Operating Expenses: General and Administrative | $366,684 | $1,172,261 | $(805,577) Professional Fees | $624,682 | $1,338,192 | $(713,510) Total Operating Expenses | $991,366 | $2,510,453 | $(1,519,087) Operating Loss | $(991,366) | $(2,510,453) | $1,519,087 Total Other Expense - Net | $(356,143) | $(33,033) | $(323,110) Net Loss | $(1,347,509) | $(2,543,486) | $1,195,977

Key Takeaways:

• General and administrative expenses decreased significantly in both the three-month and nine-month periods, primarily due to lower stock-based compensation and reduced corporate consulting and legal fees.
• Professional fees also declined substantially, again driven by lower stock-based compensation and decreased corporate consulting services.
• Other expense increased, largely due to higher interest expense on growing note payable and convertible note payable balances, as well as a loss on the change in fair value of derivative liabilities.
• Overall, Hypha Labs reported lower net losses in both periods compared to the prior year, reflecting the company’s efforts to control costs as it transitions to its new bioreactor business.

Strengths and Weaknesses

Strengths:

• Innovative bioreactor technology that could disrupt traditional mushroom production methods
• Potential to provide consumers with a convenient, efficient way to grow high-quality mushroom nutrients at home
• Experienced management team with expertise in the functional mushroom industry

Weaknesses:

• Significant operating losses and negative working capital position, raising substantial doubt about the company’s ability to continue as a going concern
• Heavy reliance on external financing to fund ongoing operations and new product development
• Unproven commercial viability of the Hypha Micropearl bioreactor

Outlook and Future Prospects

Hypha Labs faces an uncertain future as it works to complete the development and testing of its Hypha Micropearl bioreactor over the next 6-12 months. The company will need to raise additional funds, likely through the sale of equity or debt securities, in order to fund this process and the initial commercial launch of the product.

There is no guarantee that Hypha Labs will be successful in securing the necessary financing or that the Hypha Micropearl bioreactor will gain traction in the market. The company’s substantial accumulated deficit and negative working capital position raise significant doubts about its ability to continue operating as a going concern.

If Hypha Labs is able to successfully bring the Hypha Micropearl to market, the product could potentially disrupt the traditional mushroom production industry and provide consumers with a novel way to grow nutritious fungi at home. However, the company will face competition from other innovative mushroom cultivation technologies, as well as established players in the functional food and supplement space.

Overall, Hypha Labs’ future remains highly uncertain. The company’s ability to execute on its bioreactor development plans and achieve commercial success will be critical to determining whether it can overcome its current financial challenges and continue operating as a viable business. Investors and other stakeholders should closely monitor the company’s progress in the coming months and years.